Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Monthly Meeting Summary, October 13, 2009 - MenHibrix

Monthly Meeting Summary – October

Date:   October 13, 2009

As required by OVRR, the review team for MenHibrix met via e-mail to present review issues to the Chair and indicate to the BLA RPMs whether any of these issues require communication to GSK.


Members Present 
ChairJoseph Temenak, Ph.D.     
Clinical Reviewer/Labeling Meghan Ferris, M.D.
Product CMC/Serology            Mustafa Akkoyunlu, M.D. Ph.D, 

Product CMC                                    

Willie Vann, Ph.D.

Product CMC                                    

Daron Freedberg, Ph.D

Product CMC                                 

Tina Roecklein, MS


Milan Blake, Ph.D.


James E. Keller, Ph.D.


Michael Schmitt, Ph.D


Joseph George
Facilities/DMPQ                              Sean Byrd

Advertising/ Promotional Labeling    

Maryann Gallagher

Clinical Statistical Reviewer               .

Barbara Krasnicka, Ph.D

Assays Statistical Reviewer               

Tsai-Lien Lin, Ph.D.
Epidemiology  David Menschik, M.D., MPH


David Martin, M.D.

DPQ/Lot Testing Plan                                   

Rajesh Gupta, Ph.D.

DPQ/Lot Testing Plan                                   

Karen Campbell 

Lot Release                                        

Joe Quander III


Robert Wesley  
DVRPA Regulatory Project Manager                       David Staten, MPH

DVRPA Regulatory Project Manager                     

   Jason Humbert   

DBPAP Regulatory Coordinator                   

Jennifer Bridgewater, MPH


1. The Clinical Reviewer has identified issues to be included in an Information Request letter. These items will be forthcoming.

2. APLB is currently reviewing the proposed proprietary name MenHibrix and the product labeling.

3. The main outstanding issue thus far from an epidemiological standpoint is that they did not submit a draft synopsis or protocol for a phase 4 study which was requested at the pre-BLA stage. The epidemiology reviewers are working on what they would like to see in such a study and anticipate generating some comments that will need internal (DE/VSB) concurrence before forwarding to others on the BLA committee and ultimately conveying to the sponsor. GSK has indicated that they would like to discuss the topic with CBER, but that strategy will be to formulate our position first and convey comments in advance of a possible teleconference.

4. No other issues were presented. The committee will meet again in November.

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English